Photo taken from Eytan Ruppin/X
Aug 24, 2024, 18:10
First response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
“NEW FINDINGS: A recent case study reported the first response of a child with neuroblastoma and a BARD1 germline mutation to PARP inhibitors. The study demonstrates potential for further studies into HRR deficiencies in pediatric cancer.
Read more about this work, which was published in The New England Journal of Medicine.
Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, was part of this research team. Dr. Ruppin utilizes multi-disciplinary algorithmic computationally driven analysis of large-scale biomedical omics and clinical data, with an emphasis on artificial intelligence and machine/deep learning approaches.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12
Dec 21, 2024, 07:45